Quarry LP Makes New $196,000 Investment in Kura Oncology, Inc. (NASDAQ:KURA)

Quarry LP purchased a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 9,500 shares of the company’s stock, valued at approximately $196,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in KURA. Avoro Capital Advisors LLC raised its holdings in Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after acquiring an additional 870,000 shares during the period. BVF Inc. IL raised its position in Kura Oncology by 9.5% in the 4th quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock worth $106,027,000 after purchasing an additional 642,245 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after acquiring an additional 577,732 shares during the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of Kura Oncology by 281.4% during the first quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock valued at $15,581,000 after purchasing an additional 538,957 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in Kura Oncology in the 4th quarter valued at about $6,695,000.

Kura Oncology Price Performance

KURA stock opened at $19.54 on Tuesday. The business’s 50-day moving average is $20.00 and its two-hundred day moving average is $20.49. The firm has a market capitalization of $1.49 billion, a P/E ratio of -9.00 and a beta of 0.84. Kura Oncology, Inc. has a 1 year low of $7.41 and a 1 year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.53) EPS. Analysts anticipate that Kura Oncology, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Monday, August 12th. JMP Securities reiterated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Monday, August 12th. Finally, Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $30.60.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.